NRX Pharmaceuticals Inc. (NRXP) Financial Statements (2024 and earlier)

Company Profile

Business Address 1201 ORANGE STREET
WILMINGTON, DE 19801
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,595,00020,054,00027,605,000466611,079
Cash and cash equivalents4,595,00020,054,00027,605,000466611,079
Prepaid expense1,205,0003,498,0003,569,00030,35069,483 
Other current assets      
Other undisclosed current assets1,084,0002,243,0001,540,00051,642 19,114
Total current assets:6,884,00025,795,00032,714,00082,45869,48930,193
Noncurrent Assets
Asset, held-in-trust    5,967,94732,005,20570,765,966
Other noncurrent assets431,00021,00015,000   
Total noncurrent assets:431,00021,00015,0005,967,94732,005,20570,765,966
TOTAL ASSETS:7,315,00025,816,00032,729,0006,050,40532,074,69470,796,159
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:9,346,0006,931,0006,062,000609,509622,441551,099
Taxes payable   16,311
Accounts payable4,632,0002,076,0003,687,000   
Accrued liabilities4,714,0004,855,0002,375,000   
Other undisclosed accounts payable and accrued liabilities    609,509622,441534,788
Deferred revenue   292,000  
Debt 9,161,000  1,809,889  
Derivative instruments and hedges, liabilities17,00037,000 655,098  
Business combination, contingent consideration, liability   4,582,000   
Due to related parties  862,148  
Other undisclosed current liabilities 524,0008,617,000987,000  16,311
Total current liabilities:19,048,00015,585,00011,923,0003,936,644622,441567,410
Noncurrent Liabilities
Long-term debt and lease obligation     1,535,623690,000
Long-term debt, excluding current maturities     1,535,623690,000
Liabilities, other than long-term debt     416,141 
Due to related parties   416,141 
Other undisclosed noncurrent liabilities  2,822,000    
Total noncurrent liabilities:  2,822,000  1,951,764690,000
Other undisclosed liabilities      
Total liabilities:19,048,00018,407,00011,923,0003,936,6442,574,2051,257,410
Temporary equity, carrying amount     24,500,48864,538,743
Equity
Equity, attributable to parent, including:(11,733,000)7,409,00020,806,0002,113,7615,000,0015,000,006
Common stock84,00067,00059,0002,6882,8442,725
Additional paid in capital241,330,000230,339,000203,990,0002,831,0884,627,6625,036,213
Accumulated other comprehensive loss(3,000)     
Retained earnings (accumulated deficit)(253,147,000)(222,997,000)(183,243,000)(720,015)369,495(38,932)
Other undisclosed equity, attributable to parent 3,000     
Total equity:(11,733,000)7,409,00020,806,0002,113,7615,000,0015,000,006
TOTAL LIABILITIES AND EQUITY:7,315,00025,816,00032,729,0006,050,40532,074,69470,796,159

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(27,837,000)(44,335,000)(115,796,000)(907,406)(713,187)(1,006,503)
Operating loss:(27,837,000)(44,335,000)(115,796,000)(907,406)(713,187)(1,006,503)
Nonoperating income (expense)(2,313,000)4,581,00022,733,000(164,263) 1,088,915
Interest and debt expense(120,000) 121,000352,071  
Income (loss) from continuing operations before equity method investments, income taxes:(30,270,000)(39,754,000)(92,942,000)(719,598)(713,187)82,412
Other undisclosed income (loss) from continuing operations before income taxes   (121,000)(352,071)1,205,820 
Income (loss) from continuing operations before income taxes:(30,270,000)(39,754,000)(93,063,000)(1,071,669)492,63382,412
Income tax expense (2,850,000)  (17,841)(84,206)(16,311)
Other undisclosed loss from continuing operations      
Income (loss) from continuing operations:(33,120,000)(39,754,000)(93,063,000)(1,089,510)408,42766,101
Income (loss) before gain (loss) on sale of properties:(93,063,000)(1,089,510)408,42766,101
Other undisclosed net income2,970,000     
Net income (loss):(30,150,000)(39,754,000)(93,063,000)(1,089,510)408,42766,101
Other undisclosed net income attributable to parent      
Net income (loss) attributable to parent:(30,150,000)(39,754,000)(93,063,000)(1,089,510)408,42766,101
Other undisclosed net loss available to common stockholders, basic   (255,822,000) (703,894)(814,965)
Net loss available to common stockholders, diluted:(30,150,000)(39,754,000)(348,885,000)(1,089,510)(295,467)(748,864)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(30,150,000)(39,754,000)(93,063,000)(1,089,510)408,42766,101
Other comprehensive income30,153,000     
Other undisclosed comprehensive income      
Comprehensive income (loss), net of tax, attributable to parent:3,000(39,754,000)(93,063,000)(1,089,510)408,42766,101

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: